Literature DB >> 24722163

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.

Fumihiko Hirai1, Mitsuhiro Takenoyama, Kenichi Taguchi, Ryo Toyozawa, Eiko Inamasu, Gouji Toyokawa, Tsukihisa Yoshida, Yoshimasa Shiraishi, Tomoyoshi Takenaka, Masafumi Yamaguchi, Chie Ushijima, Takashi Seto, Sadanori Takeo, Yukito Ichinose.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24722163     DOI： 10.1097/JTO.0000000000000097

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.

Authors:  Wentao Hu; Yahui Liu; Jian Chen
Journal:  Oncotarget       Date:  2017-04-11

2.  KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.

Authors:  Jeong-Oh Kim; Jieun Lee; Jung-Young Shin; Ji-Eun Oh; Chan-Kwon Jung; Jae Kil Park; Sook-Whan Sung; Sang-Ju Bae; Hyun-Jung Min; Dowon Kim; Jae Yong Park; Jin-Hyoung Kang
Journal:  Diagn Pathol       Date:  2015-08-14       Impact factor: 2.644
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.